Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
Identifieur interne : 000E11 ( PubMed/Curation ); précédent : 000E10; suivant : 000E12Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
Auteurs : Thilo Van Eimeren [Canada] ; Bénédicte Ballanger ; Giovanna Pellecchia ; Janis M. Miyasaki ; Anthony E. Lang ; Antonio P. StrafellaSource :
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [ 1740-634X ] ; 2009.
English descriptors
- KwdEn :
- Benzothiazoles (pharmacology), Benzothiazoles (therapeutic use), Dopamine Agonists (pharmacology), Dopamine Agonists (therapeutic use), Frontal Lobe (drug effects), Frontal Lobe (physiopathology), Gambling (psychology), Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Magnetic Resonance Imaging, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Psychomotor Performance (drug effects), Psychomotor Performance (physiology), Reward, Risk-Taking.
- MESH :
- chemical , pharmacology : Benzothiazoles, Dopamine Agonists, Levodopa.
- chemical , therapeutic use : Benzothiazoles, Dopamine Agonists, Levodopa.
- complications : Parkinson Disease.
- drug effects : Frontal Lobe, Psychomotor Performance.
- drug therapy : Parkinson Disease.
- physiology : Psychomotor Performance.
- physiopathology : Frontal Lobe, Parkinson Disease.
- psychology : Gambling, Parkinson Disease.
- Humans, Magnetic Resonance Imaging, Male, Middle Aged, Reward, Risk-Taking.
Abstract
The neurobehavioral underpinnings of pathological gambling are not well understood. Insight might be gained by understanding pharmacological effects on the reward system in patients with Parkinson's disease (PD). Treatment with dopamine agonists (DAs) has been associated with pathological gambling in PD patients. However, how DAs are involved in the development of this form of addiction is unknown. We tested the hypothesis that tonic stimulation of dopamine receptors specifically desensitizes the dopaminergic reward system by preventing decreases in dopaminergic transmission that occurs with negative feedback. Using functional magnetic resonance imaging, we studied PD patients during three sessions of a probabilistic reward task in random order: off medication, after levodopa (LD) treatment, and after an equivalent dose of DA (pramipexole). For each trial, a reward prediction error value was computed using outcome, stake, and probability. Pramipexole specifically changed activity of the orbitofrontal cortex (OFC) in two ways that were both associated with increased risk taking in an out-of-magnet task. Outcome-induced activations were generally higher with pramipexole compared with LD or off medication. In addition, only pramipexole greatly diminished trial-by-trial correlation with reward prediction error values. Further analysis yielded that this resulted mainly from impaired deactivation in trials with negative errors in reward prediction. We propose that DAs prevent pauses in dopamine transmission and thereby impair the negative reinforcing effect of losing. Our findings raise the question of whether pathological gambling may in part stem from an impaired capacity of the OFC to guide behavior when facing negative consequences.
DOI: 10.1038/sj.npp.npp2009124
PubMed: 19741594
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E11
Links to Exploration step
pubmed:19741594Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?</title><author><name sortKey="Van Eimeren, Thilo" sort="Van Eimeren, Thilo" uniqKey="Van Eimeren T" first="Thilo" last="Van Eimeren">Thilo Van Eimeren</name><affiliation wicri:level="1"><nlm:affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, BIB-SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour-Systems Neuroscience, BIB-SN, Toronto Western Research Institute, University of Toronto, Toronto, ON</wicri:regionArea></affiliation></author><author><name sortKey="Ballanger, Benedicte" sort="Ballanger, Benedicte" uniqKey="Ballanger B" first="Bénédicte" last="Ballanger">Bénédicte Ballanger</name></author><author><name sortKey="Pellecchia, Giovanna" sort="Pellecchia, Giovanna" uniqKey="Pellecchia G" first="Giovanna" last="Pellecchia">Giovanna Pellecchia</name></author><author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M" last="Miyasaki">Janis M. Miyasaki</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19741594</idno><idno type="pmid">19741594</idno><idno type="doi">10.1038/sj.npp.npp2009124</idno><idno type="wicri:Area/PubMed/Corpus">000E11</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E11</idno><idno type="wicri:Area/PubMed/Curation">000E11</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?</title><author><name sortKey="Van Eimeren, Thilo" sort="Van Eimeren, Thilo" uniqKey="Van Eimeren T" first="Thilo" last="Van Eimeren">Thilo Van Eimeren</name><affiliation wicri:level="1"><nlm:affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, BIB-SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour-Systems Neuroscience, BIB-SN, Toronto Western Research Institute, University of Toronto, Toronto, ON</wicri:regionArea></affiliation></author><author><name sortKey="Ballanger, Benedicte" sort="Ballanger, Benedicte" uniqKey="Ballanger B" first="Bénédicte" last="Ballanger">Bénédicte Ballanger</name></author><author><name sortKey="Pellecchia, Giovanna" sort="Pellecchia, Giovanna" uniqKey="Pellecchia G" first="Giovanna" last="Pellecchia">Giovanna Pellecchia</name></author><author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M" last="Miyasaki">Janis M. Miyasaki</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></author></analytic><series><title level="j">Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</title><idno type="eISSN">1740-634X</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Benzothiazoles (pharmacology)</term><term>Benzothiazoles (therapeutic use)</term><term>Dopamine Agonists (pharmacology)</term><term>Dopamine Agonists (therapeutic use)</term><term>Frontal Lobe (drug effects)</term><term>Frontal Lobe (physiopathology)</term><term>Gambling (psychology)</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Psychomotor Performance (drug effects)</term><term>Psychomotor Performance (physiology)</term><term>Reward</term><term>Risk-Taking</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Benzothiazoles</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzothiazoles</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Frontal Lobe</term><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Frontal Lobe</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Gambling</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Reward</term><term>Risk-Taking</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The neurobehavioral underpinnings of pathological gambling are not well understood. Insight might be gained by understanding pharmacological effects on the reward system in patients with Parkinson's disease (PD). Treatment with dopamine agonists (DAs) has been associated with pathological gambling in PD patients. However, how DAs are involved in the development of this form of addiction is unknown. We tested the hypothesis that tonic stimulation of dopamine receptors specifically desensitizes the dopaminergic reward system by preventing decreases in dopaminergic transmission that occurs with negative feedback. Using functional magnetic resonance imaging, we studied PD patients during three sessions of a probabilistic reward task in random order: off medication, after levodopa (LD) treatment, and after an equivalent dose of DA (pramipexole). For each trial, a reward prediction error value was computed using outcome, stake, and probability. Pramipexole specifically changed activity of the orbitofrontal cortex (OFC) in two ways that were both associated with increased risk taking in an out-of-magnet task. Outcome-induced activations were generally higher with pramipexole compared with LD or off medication. In addition, only pramipexole greatly diminished trial-by-trial correlation with reward prediction error values. Further analysis yielded that this resulted mainly from impaired deactivation in trials with negative errors in reward prediction. We propose that DAs prevent pauses in dopamine transmission and thereby impair the negative reinforcing effect of losing. Our findings raise the question of whether pathological gambling may in part stem from an impaired capacity of the OFC to guide behavior when facing negative consequences.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19741594</PMID><DateCreated><Year>2009</Year><Month>11</Month><Day>10</Day></DateCreated><DateCompleted><Year>2010</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-634X</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>13</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?</ArticleTitle><Pagination><MedlinePgn>2758-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/sj.npp.npp2009124</ELocationID><Abstract><AbstractText>The neurobehavioral underpinnings of pathological gambling are not well understood. Insight might be gained by understanding pharmacological effects on the reward system in patients with Parkinson's disease (PD). Treatment with dopamine agonists (DAs) has been associated with pathological gambling in PD patients. However, how DAs are involved in the development of this form of addiction is unknown. We tested the hypothesis that tonic stimulation of dopamine receptors specifically desensitizes the dopaminergic reward system by preventing decreases in dopaminergic transmission that occurs with negative feedback. Using functional magnetic resonance imaging, we studied PD patients during three sessions of a probabilistic reward task in random order: off medication, after levodopa (LD) treatment, and after an equivalent dose of DA (pramipexole). For each trial, a reward prediction error value was computed using outcome, stake, and probability. Pramipexole specifically changed activity of the orbitofrontal cortex (OFC) in two ways that were both associated with increased risk taking in an out-of-magnet task. Outcome-induced activations were generally higher with pramipexole compared with LD or off medication. In addition, only pramipexole greatly diminished trial-by-trial correlation with reward prediction error values. Further analysis yielded that this resulted mainly from impaired deactivation in trials with negative errors in reward prediction. We propose that DAs prevent pauses in dopamine transmission and thereby impair the negative reinforcing effect of losing. Our findings raise the question of whether pathological gambling may in part stem from an impaired capacity of the OFC to guide behavior when facing negative consequences.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Eimeren</LastName><ForeName>Thilo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, BIB-SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballanger</LastName><ForeName>Bénédicte</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Pellecchia</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Miyasaki</LastName><ForeName>Janis M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Strafella</LastName><ForeName>Antonio P</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>64423</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>MOP-64423</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>83619PEU5T</RegistryNumber><NameOfSubstance UI="C061333">pramipexole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 1995 Jun;2(2):157-65</RefSource><PMID Version="1">9343598</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2004 Apr;127(Pt 4):851-9</RefSource><PMID Version="1">15013954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 2007 Dec;61(12):1013-8</RefSource><PMID Version="1">17853435</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Psychol Appl. 2002 Jun;8(2):75-84</RefSource><PMID Version="1">12075692</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroreport. 2001 Dec 4;12(17):3683-7</RefSource><PMID Version="1">11726774</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurophysiol. 1998 Aug;80(2):947-63</RefSource><PMID Version="1">9705481</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Oct 10;67(7):1258-61</RefSource><PMID Version="1">17030761</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3181-9</RefSource><PMID Version="1">18640909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Depress Anxiety. 2000;11(4):185-6</RefSource><PMID Version="1">10945141</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroepidemiology. 2003 Sep-Oct;22(5):297-304</RefSource><PMID Version="1">12902625</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 May;132(Pt 5):1376-85</RefSource><PMID Version="1">19346328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2008 Dec;65(12):1604-11</RefSource><PMID Version="1">19064747</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 2000 Nov;157(11):1789-98</RefSource><PMID Version="1">11058476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Neurosci. 2002 Apr;116(2):321-33</RefSource><PMID Version="1">11996317</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2001 May;30(2):619-39</RefSource><PMID Version="1">11395019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2001 Jul 5;412(6842):43-8</RefSource><PMID Version="1">11452299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychologia. 2000;38(5):596-612</RefSource><PMID Version="1">10689037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2000 Jul;12(1):20-7</RefSource><PMID Version="1">10875899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):972-5</RefSource><PMID Version="1">15201352</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2002 Oct 10;36(2):241-63</RefSource><PMID Version="1">12383780</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychopharmacol. 2008 Feb;28(1):45-51</RefSource><PMID Version="1">18204340</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2006 Sep 13;26(37):9530-7</RefSource><PMID Version="1">16971537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2007 Nov 23;318(5854):1309-12</RefSource><PMID Version="1">17962524</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1997 Apr 24;386(6627):830-3</RefSource><PMID Version="1">9126741</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Treat Options Neurol. 2007 May;9(3):189-97</RefSource><PMID Version="1">17445496</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2007 Apr 11;27(15):4019-26</RefSource><PMID Version="1">17428979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropharmacology. 2009;56 Suppl 1:3-8</RefSource><PMID Version="1">18617195</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychologia. 2006;44(10):1663-73</RefSource><PMID Version="1">16730032</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1999 Apr 22;398(6729):704-8</RefSource><PMID Version="1">10227292</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Jun 13;66(11):1750-2</RefSource><PMID Version="1">16769956</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2005 Feb;8(2):147-8</RefSource><PMID Version="1">15643429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2004 Dec 10;306(5703):1940-3</RefSource><PMID Version="1">15528409</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2002 Apr;15(4):870-8</RefSource><PMID Version="1">11906227</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropharmacology. 2004;47 Suppl 1:3-13</RefSource><PMID Version="1">15464121</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2003 Jan 1;23(1):303-7</RefSource><PMID Version="1">12514228</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2002 Jul;5(7):625-6</RefSource><PMID Version="1">12055635</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2009 May;12(5):535-40</RefSource><PMID Version="1">19396166</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Clin Psychopharmacol. 2008 Dec;16(6):565-70</RefSource><PMID Version="1">19086777</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Aug 12;61(3):422-3</RefSource><PMID Version="1">12913220</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2003 Apr 24;38(2):329-37</RefSource><PMID Version="1">12718865</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurophysiol. 2007 Sep;98(3):1428-39</RefSource><PMID Version="1">17615124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Alcohol Depend. 2007 Mar 16;87(2-3):233-40</RefSource><PMID Version="1">16997508</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Biobehav Rev. 2006;30(1):1-23</RefSource><PMID Version="1">15935475</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2007 Sep;130(Pt 9):2412-24</RefSource><PMID Version="1">17626038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cereb Cortex. 2001 Dec;11(12):1136-43</RefSource><PMID Version="1">11709484</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005715" MajorTopicYN="N">Gambling</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="Y">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012309" MajorTopicYN="N">Risk-Taking</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">CAMS1534</OtherID><OtherID Source="NLM">PMC2972251</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19741594</ArticleId><ArticleId IdType="pii">npp2009124</ArticleId><ArticleId IdType="doi">10.1038/sj.npp.npp2009124</ArticleId><ArticleId IdType="pmc">PMC2972251</ArticleId><ArticleId IdType="mid">CAMS1534</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000E11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:19741594
|texte= Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19741594" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |